Neuromodulation by Medtrode Inc.
 
 
 
Corporate
Overview
History
Scientific Advisory Board
Management
Investors
Overview
“A spin-off from decades of research in electrophysiology, neurostimulation utilizes pacemaker technology to treat neurological conditions and is one of the hottest and fastest growing niches in the medical devices industry” (Frost & Sullivan, 2004).
   
Medtrode Inc. is a medical device company developing a portfolio of next generation neurostimulation therapies that enable site-specific delivery of electrical stimulation used to treat neurological and other disorders. At the core of the delivery system is a novel, patented multichannel electrode that is easier and safer to implant yet offers unprecedented therapy configuration. Matched with a true multichannel implantable pulse generator (IPG), the total system will be the only device on the market that will empower clinicians to record and reconfigure the electrical field, post-implantation. The reduced size of our MCE design and the ability to simultaneously record and stimulate with one device also permits additional therapies that are unachievable with current devices.

In addition to our unique multichannel (MCE) technology, Medtrode has also developed a new implant system that greatly streamlines the surgical procedure for neurosurgeons. Medtrode is also pursuing a joint development program with a well known international medical device manufacturer that is currently supplying clinically proven implantable systems in a separate, but related field.

Our unique technology streamlines DBS procedures bringing down the cost of the surgery and optimizing the cost/benefit ratio. Reducing the cost and complexity of DBS surgery will drive market adoption for DBS, in which market penetration is still less than 5%. The growing population of older Americans suffering from conditions indicated for neurostimulation is also a strong driver for the neurostimulation market.
  "The core benefits that all neurostimulation systems have over the drug therapies and surgeries used to treat the same conditions are that neurostimulation is a less-invasive, quickly-testable, programmable, localized, and a reversible adjunctive therapy that can help properly selected patients" (Frost & Sullivan).
 

The deep brain stimulation as well as the total neuromodulation market in U.S. alone is expected to explode in the next 5 years, reaching $1.1 billion and $3.6 billion accordingly. Deep Brain Stimulation is currently approved for Parkinson’s disease, essential tremor and dystonia. Indications under evaluation include but are not limited to treating epilepsy, depression, compulsive disorders, Alzheimer’s and other neurological disorders.
   
 
 
Copyright Medtrode Inc. 2006